This Month
Psychedelics as a serious investment? These billionaires think so
Australia is among the first countries to use the drugs for treating anxiety, depression and PTSD. A decision in the United States could be pivotal.
- Michael Smith
Pfizer invests $150m in Melbourne to fight superbugs
The US pharma giant says the federal government must do more to ensure Australians can access new drugs designed to fight deadly superbugs.
- Michael Smith
Ramsay tips lower earnings, hospital capex weak
Ramsay Health Care says full-year earnings will be weaker than expected as it flags writedowns on its European operations.
- Michael Smith
- Exclusive
- Medibank Private
Hospitals seek right to boycott big insurers from funding talks
Catholic-operated private hospitals want a major shake-up of the way they negotiate funding deals with health insurers, in an escalation of tensions between the two sides.
- Michael Smith
ResMed says sales growth defies weight-loss fears
Chief executive Mick Farrell says he is confident the company has put to bed investor fears that weight-loss drugs will hurt sales of its sleep apnoea products.
- Michael Smith
July
- Opinion
- Chanticleer
The PE takeover battle that is like pulling teeth
Once a board has decided a takeover isn’t about the highest price, it enters the deal-making twilight zone. This one is a doozy.
- Anthony Macdonald
Inside the stoush between private hospitals and health insurers
As finances deteriorate, insurers and providers are slugging it out over how to overhaul a healthcare system which has not seen serious reform in decades.
- Michael Smith
This two-day, $42k medical appointment is for people who aren’t sick
Companies are tapping into a desire for a long and healthy life with packages that include sophisticated diagnostic options.
- Mark Ellwood
It’s a banker bonanza as Permira eyes its $4b I-MED payday
The firm’s dealmakers have tapped Jefferies to join their sell-side advisory lineup, alongside Morgan Stanley – which has kept close to the company for years.
- Sarah Thompson, Kanika Sood and Emma Rapaport
Telix shares hit new high on upgraded revenue forecast
The biotech’s shares double in value this year due to strong sales in the United States for its prostate cancer imaging product.
- Michael Smith
Ramsay’s French asset posts weaker earnings, launches debt refinancing
The healthcare provider says lower government subsidies and inflation are hurting the performance of its Ramsay Sante business.
- Michael Smith
- Opinion
- Opinion
Vested interests at play in the chronic disease explosion
A search for good nutrition opened a Pandora’s box of snake oil salesmen and crackpot solutions. It also provided clues to the surging levels of chronic disease.
- Tony Boyd
- Opinion
- Investing
How to invest in the golden age of health disruption
Investing in healthcare in today’s market combines exposure to two key drivers – structural demand growth and disruptive innovation.
- Andrew McAuley
Are you overweight or obese? Depends on where you carry your fat
European experts have developed a new framework to modernise the staging, diagnosis and management of obesity.
- Jill Margo
Forced smiles: Crescent Capital, Genesis get their fangs out
Pacific Smiles has been in a holding pattern since the dispute broke out.
- Sarah Thompson, Kanika Sood and Emma Rapaport
I-MED snaps up US teleradiology player StatRad
Aussie imaging giant I-MED is hoping to recreate its fast-growing teleradiology business in the US with a major acquisition.
- Tess Bennett
- Exclusive
- Venture capital
Frazis unveils venture capital fund, makes first investments
The Gen Y tech investor has nabbed stakes in a dozen start-ups in tech, health and e-commerce, thanks to $10 million raised from wealthy investors.
- Tom Richardson
June
Why people with cancer don’t get the full benefit of clinical trials
Australian researchers say regulators should mandate the requirement to share data.
- Jill Margo
- Exclusive
- Industrial relations
Nurses identify ‘$1.2bn’ in savings for 15 per cent pay rise
Deloitte’s report for the NSW nurses’ union found the state government may have missed out on more than $3 billion in Commonwealth funding due to inaccurate data.
- David Marin-Guzman
Radiology’s AI future and deregulation help end years of bad blood
The No.1 player in an industry sets the tone. And in radiology, the tone is deals, deals, deals.
- Anthony Macdonald
